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Introduction
Chinese Hamster Ovary (CHO) cells are widely used for
the large scale production of recombinant biopharmaceu-
ticals. These cells have been extensively characterised and
approved by regulatory authorities for production of bio-
pharmaceuticals. During the last years more and more
cell-line engineering strategies have been developed to
enhance productivity and quality. CHO cell line engineer-
ing work has made remarkable progress in optimizing pro-
ducts or titers by focusing on manipulating single genes
and selecting clones with desirable traits. In this work it is
shown how cell line engineering approaches enable the
expression of a challenging to express “novel therapeutic
protein”. The expression of the “novel therapeutic protein”
in CHO cells resulted in significant reduced cell growth as
well as low productivity.
Results
Transcriptomics analysis
Using customised CHO specific microarrays the gene
expression profile of CHO cells expressing the “novel ther-
apeutic protein” was analysed. The expression of the
“novel therapeutic protein” resulted in a significant down-
regulation of all mitochondria encoded genes. The down-
regulation was more than 40 fold for some of these genes
(Figure 1A). This massive reduced transcription of mito-
chondrial encoded genes was very likely causing the
reduced cell growth and reduced expression of the “novel
therapeutic protein”. A decrease in mitochondrial function
reduces overall metabolic efficiency and a change of meta-
bolic pathways could also be detected on gene expression
level. Additionally the expression of “gene A” was detected
in the applied CHO cell line, which might have the poten-
tial to trigger the down regulation of the mitochondrial
encoded genes in the presence of the “novel therapeutic
protein”.
Gene knockdown using shRNA (short hairpin RNA)
technique
A variety of cell line engineering approaches were per-
formed to circumvent cell growth inhibition caused by
down regulation of mitochondrial encoded genes with the
aim to improve expression of the “novel therapeutic pro-
tein”. In the first approach the expression of “gene A”,
which was assumed to trigger the down regulation of the
mitochondrial encoded genes, was repressed more than 10
fold using shRNA technique. shRNA is a sequence of
RNA that makes a tight hairpin turn that can be used to
silence target gene expression via RNA interference.
Expression of shRNA was accomplished by delivery of
stable integrated plasmids. Cells with reduced expression
of “gene A” showed an improved cell growth and higher
expression of the “novel therapeutic protein” (Figure 1 B).
However cell growth was still repressed, although to a
lower extent, and titers were still lower in comparison to
other therapeutic protein formats. Despite the significant
decrease in the expression of “gene A”, the remaining
“protein A” seemed to be sufficient to trigger these effects
although to a lower magnitude.
Gene knockout using zinc finger nucleases (ZFN)
To completely eliminate the cell growth inhibition a
knockout of “gene A” was performed using ZFN technique.
ZFNs are artificial restriction enzymes generated by fusing
a zinc finger DNA-binding domain to a DNA-cleavage
domain. Plasmids encoding ZFNs (specifically designed to
detect and cleave “gene A”) were transiently transfected in
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Figure 1 A highlights the reduced expression of mitochondria encoded genes in CHO cells expressing the “novel therapeutic protein” in
comparison to parental CHO cells. The y-axis shows the gene expression values in signal intensities. B: Batch culture titers of the “novel
therapeutic protein” in shake flask are shown. Titer for CHO WT cells are labeled in red, titer for CHO cells with reduced expression of gene A
(shRNA approach) are labeled in yellow and titer for CHO cells with non-functional gene A (knockout) are labeled in green. C: Cell growth of
CHO WT cells and CHO knockout (KO) cells with and without “novel therapeutic protein” in shake flasks. Y-axis shows viable cell density and
x-axis cultivation time. D: Gene expression of mitochondrial encoded genes is not reduced in all three generated CHO KO cell lines with the
“novel therapeutic protein”. Hierarchical clustering reveals that the “novel therapeutic protein” does not affect the gene expression profile of the
KO cell lines. In contrast the “novel therapeutic protein” has a clear effect on the WT cell line.
Laux et al. BMC Proceedings 2013, 7(Suppl 6):P1
http://www.biomedcentral.com/1753-6561/7/S6/P1
Page 2 of 3
the parental CHO cell line. ZFN cleaves “gene A” which is
then repaired by non-homologous end joining. This is
often error prone and resulted in the generation of mutant
alleles. Three clones were identified with mutation in both
alleles of “gene A” resulting in shifts of the reading frame
and therefore only nonfunctional premature termination
products are encoded.
Knockout of “gene A” resulted in complete elimination
of cell growth inhibition and the expression of mitochon-
dria encoded genes (Figure 1D) was restored to levels
comparable to parental CHO cells. In addition there was
no change in the expression of genes that are involved in
metabolic pathways. Most striking is the significant
improved cell growth and productivity resulting in a 6-7
fold titer increase using this genetically engineered
knockout cell line (Figure 1B and 1C).
Conclusion
This example illustrates that transcriptomic analysis can
support and facilitate the understanding and solving of spe-
cific issues during the expression of therapeutic proteins.
Novel cell line engineering methods as ZFN technique are
powerful tools to solve definite issues in production of
therapeutic proteins in biopharmaceutical industry.
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